Pharma Mar SA

PHM

Equity

ISIN ES0169501022 / Valor 56130572

BME Bolsas y Mercados Espanoles - Renta Variable (2025-11-21)

EUR 75.65-3.32%

Pharma Mar SA
UMushroom community rating:

0.00 0 votes No rating yet

NegativeNeutralPositive

About company

Pharma Mar SA, headquartered in Madrid, Spain, is a biopharmaceutical company specializing in the development of oncology drugs derived from marine biodiversity. Established in 1986, the company has a strong focus on researching and developing treatments for rare cancers, leveraging the unique antitumor properties found in marine organisms. Pharma Mar commercializes three main drugs, which, through partnerships with 18 companies, are distributed in over 70 countries. The company has a significant international presence with subsidiaries in Germany, France, Italy, Belgium, Austria, Switzerland, and the United States. Pharma Mar is committed to reinvesting its profits and partner revenues into research and development, as well as the continuous training of its team, to advance its mission of providing innovative cancer therapies.

Summarized from source with an LLMView SourceSector: Healthcare

Total Revenue Growth

PharmaMar SA's total revenue reached €174.9 million in 2024, reflecting an 11% increase from €156.9 million in 2023.

Increase in Royalties

Royalties from sales surged by 18% to €61.3 million, driven primarily by a 15% growth in royalties from Jazz Pharmaceuticals for lurbinectedin sales in the U.S.

Revenue from License Agreements

Revenue from license agreements grew by 38% to €46.5 million, supported by significant payments from Janssen and Luye for trabectedin and lurbinectedin licenses, respectively.

Research and Development Investment

R&D investment increased by 4% to €103.5 million, with the oncology segment alone seeing a 13% rise to €94.4 million, facilitating advancements in key clinical trials.

EBITDA and Net Profit

EBITDA surged to €13.0 million from €2.1 million in 2023, while net profit soared to €26.1 million, up from €1.1 million the previous year, highlighting improved operational efficiency.

Oncology Sales Performance

Total oncology sales amounted to €66.5 million in 2024, a slight decrease from €70.7 million in 2023, impacted by fluctuations in Yondelis® and adjustments related to Zepzelca® revenue.

Summarized from source with an LLMView Source

Key figures

3.49%1Y

16.4%3Y

-18.8%5Y

Performance

44.4%1Y

40.6%3Y

44.2%5Y

Volatility